3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
3
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Conditions
Carcinoma, Non-Small-Cell Lung
8
Neoplasms
7
Melanoma
5
Squamous Cell Carcinoma of Head and Neck
4
Head and Neck Neoplasms
4
Triple Negative Breast Neoplasms
3
Colorectal Neoplasms
3
Carcinoma, Renal Cell
3
Solid Tumor, Adult
2
Prostatic Neoplasms
2
Pancreatic Neoplasms
2
Ovarian Neoplasms
2
Neoplasm Metastasis
2
Bites and Stings
2
Turcot syndrome
1
Small Cell Lung Carcinoma
1
Skin Neoplasms
1
Sarcoma
1
Recurrence
1
Rectal Neoplasms
1
Oligoprogressive
1
Multiple Myeloma
1
Liver Neoplasms
1
Kidney Neoplasms
1
Histiocytoma, Malignant Fibrous
1
First-line Advanced NSCLC Patients
1
Esophageal Squamous Cell Carcinoma
1
Endometrial Neoplasms
1
Dermatofibrosarcoma
1
Colonic Neoplasms
1
Interventions
Doxorubicin
33
pembrolizumab
16
Gemcitabine
15
eribulin
10
Irinotecan
10
olaratumab
9
Trabectedin
9
pazopanib
8
Docetaxel
8
Injections
7
Cyclophosphamide
7
Nivolumab
6
Fluorouracil
6
anlotinib
5
Temozolomide
5
Ipilimumab
5
Ifosfamide
5
Bevacizumab
5
tazemetostat
4
ridaforolimus
4
Drug Therapy
4
Cetuximab
4
Carboplatin
4
toripalimab
3
surufatinib
3
spartalizumab
3
ganitumab
3
entrectinib
3
conatumumab
3
belinostat
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Sarcoma
×
Immune Checkpoint Inhibitors
×
Clear all
NCT04673942
2024-10-26
BETA-PRIME
EpicentRx, Inc.
Phase 2
Recruiting
140 enrolled